for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Dr.Reddy's Laboratories Ltd

REDY.NS

Latest Trade

4,573.50INR

Change

-9.55(-0.21%)

Volume

1,665,377

Today's Range

4,560.55

 - 

4,707.00

52 Week Range

2,351.20

 - 

4,707.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
4,583.05
Open
4,590.00
Volume
1,665,377
3M AVG Volume
25.25
Today's High
4,707.00
Today's Low
4,560.55
52 Week High
4,707.00
52 Week Low
2,351.20
Shares Out (MIL)
165.86
Market Cap (MIL)
758,571.30
Forward P/E
30.07
Dividend (Yield %)
0.55

Next Event

Q2 2021 Dr.Reddy's Laboratories Ltd Earnings Release

Latest Developments

More

India's Dr.Reddy's Laboratories June-Quarter Consol Profit Falls

Dr.Reddy's Laboratories Gets Approval Of Xeglyze (Abametapir) Lotion, 0.74%, In U.S.

Dr.Reddy's Laboratories Says Launch Of Abiraterone Acetate Tablets In U.S. Market

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Dr.Reddy's Laboratories Ltd

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients and intermediates (API) or bulk drugs. Proprietary Products segment focuses on the research, development and manufacture of differentiated formulations and new chemical entities. These products fall within the dermatology and neurology therapeutic areas, and are marketed and sold through its subsidiary, Promius Pharma, LLC.

Industry

Biotechnology & Drugs

Contact Info

8-2-337, Road No.3 Banjara Hills

500-034

India

+91.40.49002900

http://www.drreddys.com/

Executive Leadership

Satish K. Reddy

Chairman of the Board

G. V. Prasad

Co-Chairman of the Board, Managing Director

Saumen Chakraborty

President, Chief Financial Officer and Global Head of ITBPE, Legal and Compliance and FMCRE

Erez Israeli

Chief Executive Officer

Patrick Aghanian

Chief Executive Officer, European Generics

Key Stats

2.49 mean rating - 39 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2018

142.8K

2019

153.9K

2020

174.6K

2021(E)

189.6K
EPS (INR)

2018

56.960

2019

113.090

2020

218.360

2021(E)

156.944
Price To Earnings (TTM)
39.16
Price To Sales (TTM)
4.19
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
24.42
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Fujifilm to partner with Dr. Reddy's to sell Avigan as COVID-19 treatment

Japan's Fujifilm Holdings Corp announced a deal with India's Dr Reddy's Laboratories and Dubai-based Global Response Aid (GRA) to sell its anti-flu drug Avigan for COVID-19 treatment globally excluding Japan, China and Russia.

Fujifilm to partner with Dr. Reddy's to sell Avigan overseas as COVID-19 treatment

Fujifilm Holdings Corp said on Wednesday it was partnering with Dr Reddy's Laboratories to sell the anti-flu drug Avigan in India and elsewhere to treat COVID-19, the respiratory disease caused by the coronavirus.

BRIEF-Dr.Reddy's Laboratories Says Launch Of Abiraterone Acetate Tablets In U.S. Market

* DR.REDDY'S LABORATORIES LTD SAYS LAUNCH OF ABIRATERONE ACETATE TABLETS USP, 250 MG IN U.S. MARKET. Source text for Eikon: Further company coverage:

BRIEF-Dr. Reddy's Laboratories Enters Into Licensing Agreement With Gilead Sciences For Remdesivir

* DR. REDDY'S LABORATORIES ENTERS INTO A LICENSING AGREEMENT WITH GILEAD SCIENCES FOR REMDESIVIR

BRIEF-Dr.Reddy's Labs Announces Launch Of Colchicine Tablets In U.S. Market

* ANNOUNCES LAUNCH OF COLCHICINE TABLETS USP, 0.6 MG IN U.S. MARKET Source text for Eikon: Further company coverage:

BRIEF-Dr.Reddy's Completes Acquisition Of Some Business Divisions Of Wockhardt

* COMPLETES ACQUISITION OF SELECT BUSINESS DIVISIONS OF WOCKHARDT Source text for Eikon: Further company coverage:

BRIEF-Midatech Pharma Enters Into Research Collaboration With Dr Reddy's

* MIDATECH PHARMA - ENTERED INTO A RESEARCH COLLABORATION WITH DR REDDY'S Source text for Eikon: Further company coverage:

BRIEF-Dr.Reddy's Labs Gets EIR From U.S. FDA For Medchal-Malkajgiri Facility

* INSPECTION CLASSIFICATION OF MEDCHAL-MALKAJGIRI FACILITY DETERMINED AS "NO ACTION INDICATED" Source text for Eikon: Further company coverage:

BRIEF-Dr.Reddy's Re-Appoints G V Prasad As Whole-Time Director Designated As Co-Chairman, MD

* RE-APPOINTS G V PRASAD AS WHOLE-TIME DIRECTOR DESIGNATED AS CO-CHAIRMAN AND MD FOR FURTHER PERIOD OF 5 YEARS Source text for Eikon: Further company coverage:

BRIEF-India's Dr.Reddy's Laboratories March Qtr Consol Profit Rises

* MARCH QUARTER CONSOL PROFIT 7.64 BILLION RUPEES VERSUS PROFIT OF 4.34 BILLION RUPEES YEAR AGO

BRIEF-Dr.Reddy's Laboratories -Gets EIR From US FDA For Formulations Plant-3 In Hyderabad

* DR.REDDY'S LABORATORIES LTD -RECEIVED ESTABLISHMENT INSPECTION REPORT (EIR) FROM US FDA FOR FORMULATIONS MANUFACTURING PLANT-3 IN HYDERABAD Source text for Eikon: Further company coverage:

BRIEF-UPS Reports Collaboration With Dr. Reddy's Lab To Get 30 Tons Of Pharmaceuticals From India To U.S.

* UPS - ANNOUNCED A COLLABORATION WITH DR. REDDY'S LABORATORIES TO GET 30 TONS OF PHARMACEUTICALS FROM INDIA TO UNITED STATES VIA EUROPE Source text for Eikon: Further company coverage:

BRIEF-Dr. Reddy's Srikakulam Plant Gets "NAI" From U.S. FDA

* FACILITY IS DETERMINED AS "NO ACTION INDICATED" Source text for Eikon: Further company coverage:

BRIEF-Dr.Reddy's Laboratories Says All Facilities Under U.S. FDA Warning Now Under VAI Status

* RECEIVED THE ESTABLISHMENT INSPECTION REPORT (EIR) FROM US FDA FOR SRIKAKULAM FACILITY

BRIEF-Dr.Reddy's Laboratories Gets Approval For NDA, Elyxyb In U.S.

* GETS APPROVAL FOR NDA, ELYXYB™ (CELECOXIB ORAL SOLUTION) 25 MG/ML, IN U.S.

BRIEF-Dr.Reddy's Labs Announces Launch Of Desmopressin Acetate Injection In U.S. Market

* ANNOUNCES LAUNCH OF DESMOPRESSIN ACETATE INJECTION USP, 4 MCG/ML IN U.S. MARKET Source text for Eikon: Further company coverage:

BRIEF-FDA Approves Dr. Reddy's Laboratories' Elyxyb Oral Solution For Acute Treatment Of Migraine With Or Without Aura In Adults

* FDA GRANTS APPROVAL FOR ELYXYB ORAL SOLUTION INDICATED FOR ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS TO DR. REDDY’S LABORATORIES

BRIEF-Dr.Reddy's Re-Schedules Board Meeting To Consider Results For FY Ended March 31

* IN VIEW OF COVID-19 SITUATION, BOARD MEETING TO CONSIDER RESULTS FOR FY ENDED MARCH 31 NOW RE-SCHEDULED TO MAY 20 Source text for Eikon: Further company coverage:

BRIEF-Dr.Reddy's Laboratories Announces Launch Of Fenofibrate Tablets USP In U.S. Market

* DR.REDDY'S LABORATORIES LTD -ANNOUNCES LAUNCH OF FENOFIBRATE TABLETS USP, IN U.S. MARKET Source text for Eikon: Further company coverage:

BRIEF-Dr.Reddy's Laboratories - Got EIR From U.S. FDA For Audit Of API Manufacturing Plant 5 In Telangana

* DR.REDDY'S LABORATORIES - GOT ESTABLISHMENT INSPECTION REPORT FROM U.S. FDA FOR AUDIT OF API MANUFACTURING PLANT 5 IN TELANGANA Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up